Asset Management One Co. Ltd. Purchases 5,072 Shares of STERIS plc $STE

Asset Management One Co. Ltd. raised its position in STERIS plc (NYSE:STE) by 5.4% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 98,487 shares of the medical equipment provider’s stock after acquiring an additional 5,072 shares during the quarter. Asset Management One Co. Ltd.’s holdings in STERIS were worth $24,366,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of STE. Spurstone Advisory Services LLC acquired a new stake in STERIS in the 2nd quarter valued at about $29,000. Geneos Wealth Management Inc. lifted its position in shares of STERIS by 416.0% in the first quarter. Geneos Wealth Management Inc. now owns 129 shares of the medical equipment provider’s stock valued at $29,000 after buying an additional 104 shares during the last quarter. TruNorth Capital Management LLC acquired a new stake in shares of STERIS in the third quarter valued at approximately $37,000. Loomis Sayles & Co. L P bought a new position in STERIS during the second quarter worth $54,000. Finally, Generali Investments Management Co LLC acquired a new position in STERIS in the 2nd quarter valued at about $56,000. 94.69% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, VP Julia Madsen sold 5,008 shares of the stock in a transaction that occurred on Friday, November 21st. The shares were sold at an average price of $262.00, for a total transaction of $1,312,096.00. Following the sale, the vice president owned 10,710 shares in the company, valued at approximately $2,806,020. This trade represents a 31.86% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Renato Tamaro sold 5,036 shares of STERIS stock in a transaction that occurred on Tuesday, November 18th. The shares were sold at an average price of $257.55, for a total transaction of $1,297,021.80. Following the completion of the transaction, the vice president directly owned 5,695 shares in the company, valued at $1,466,747.25. This trade represents a 46.93% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 25,044 shares of company stock worth $6,586,218 over the last ninety days. Corporate insiders own 1.07% of the company’s stock.

STERIS Stock Up 2.6%

NYSE STE opened at $256.63 on Tuesday. The company has a current ratio of 2.37, a quick ratio of 1.63 and a debt-to-equity ratio of 0.27. The company has a market cap of $25.19 billion, a price-to-earnings ratio of 36.87 and a beta of 1.03. The company has a 50 day moving average of $255.78 and a 200-day moving average of $245.26. STERIS plc has a 1-year low of $203.35 and a 1-year high of $268.60.

STERIS (NYSE:STE) last posted its quarterly earnings data on Wednesday, November 5th. The medical equipment provider reported $2.47 EPS for the quarter, topping analysts’ consensus estimates of $2.38 by $0.09. The firm had revenue of $1.46 billion for the quarter, compared to analyst estimates of $1.43 billion. STERIS had a return on equity of 14.43% and a net margin of 12.07%.During the same quarter last year, the company earned $2.14 EPS. STERIS has set its FY 2026 guidance at 10.150-10.30 EPS. On average, equities research analysts expect that STERIS plc will post 9.08 earnings per share for the current fiscal year.

STERIS Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, December 18th. Investors of record on Tuesday, November 18th were given a dividend of $0.63 per share. The ex-dividend date of this dividend was Tuesday, November 18th. This represents a $2.52 annualized dividend and a yield of 1.0%. STERIS’s dividend payout ratio is currently 36.21%.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on STE. Weiss Ratings restated a “buy (b)” rating on shares of STERIS in a report on Tuesday, October 14th. Wall Street Zen raised STERIS from a “buy” rating to a “strong-buy” rating in a report on Sunday, September 14th. Seven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, STERIS presently has a consensus rating of “Moderate Buy” and an average target price of $273.50.

STERIS Company Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.